Seasonal influenza vaccine delivered by intradermal microinjection: A randomised controlled safety and immunogenicity trial in adults

被引：97

作者：

Leroux-Roels, Isabel ^{[1
]}

Vets, Eva ^{[2
]}

Freese, Ralf ^{[3
]}

Seiberling, Michael ^{[4
]}

Weber, Francoise ^{[5
]}

Salamand, Camille ^{[5
]}

Leroux-Roels, Geert ^{[1
]}

机构：

[1] Ghent Univ & Hosp, Ctr Vaccinol, B-9000 Ghent, Belgium

[2] SGS Biopharma, Res Univ Stuivenberg, Antwerp, Belgium

[3] Univ Med Ctr Hamburg Eppendorf, CTC N, MediGate GmbH, Clin Trial Ctr, Hamburg, Germany

[4] Swiss Pharma Contract, Allschwil, Switzerland

[5] Sanofi Pasteur, Lyon, France

来源：

VACCINE | 2008年 / 26卷 / 51期

关键词：

Influenza vaccine; Intradermal; Microinjection; Immune response; Haemagglutination inhibition;

D O I：

10.1016/j.vaccine.2008.09.078

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Influenza vaccines remain largely underused. A promising alternative to Current intramuscular vaccines is a trivalent inactivated influenza vaccine (TIV) delivered using a microinjection system to offer a less invasive and possibly more acceptable vaccination. A phase 11, multicentre, randomised open-label study in 978 healthy adults (18-57 years) evaluated the immunogenicity and safety of intradermal TIV. Subjects received a 0.1 ml injection of intradermal TIV, containing 9 mu g of haemagglutinin (HA) per strain (it = 588) or a conventional 0.5 ml intramuscular vaccine (15 mu g of HA/strain: n = 390). Intradermal,11 TIV induced non-inferior humoral immune responses against all three strains and superior responses against both A strains (H1N1, H3N2) compared with the control. Both vaccines were well tolerated. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：6614 / 6619

页数：6

共 26 条

[1]

[Anonymous], 2005, Wkly Epidemiol Rec, V80, P279

[2] Antibody responses after dose-sparing intradermal influenza vaccination [J].